This site uses cookies. By using this site you agree to receiving cookies. View Policy.

287%
Raised
£143,630
Investors
287
Target
£50,000
Equity
8.74%
Pre-money valuation
£1,500,000

Aiming to resolve the problem of DNA data breach & exploitation by providing individual users with a technology to sequence, store, manage & commercialise their genomic data. We will help users to protect the most valuable piece of private information they will ever possess: their DNA data.

  • A tech start-up in the rapidly evolving Genome Management marketplace
  • A robust, decentralised, blockchain technology
  • An ambition to engage with pharmaceutical companies and research organisations
  • Giving individuals control over their DNA data

Idea

Sequencing of human genomes is rapidly becoming an affordable technology for general consumers.

The drop in operational costs for this technology, combined with the enormous potential for personalised medicine, means that we are looking at a future where all of humanity, all 7B+ people could have their genomes sequenced. The potential for exploitation of people’s personal genomic data is, therefore, a huge concern.

Securely storing genomes in a query-able way is an unrealised necessity that with blockchain technology is now realisable. Genomes.io aims to sequence 1 billion genomes and to provide private and secure B2C and B2B product services, such as our marketplace and store, on top of them. We are developing decentralised technology which uses proof of computations to perform queries on the human genome, without compromising any of the genomic sequence itself, safeguarding the data and privacy of our individual users at all times.

We have recently been acknowledged as 1 of the 5 hottest start-ups in Genome Data Management and received collaborative requests from a number of parties in the market.

We are raising a £50k investment to further advance our technology so our users are always able to safely manage their genomic data and to achieve our commercial objectives working as a Genome Data Management tool with partners in the Pharmaceutical and Research field.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the genomes.io pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

genomes.io has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Seed Enterprise Investment Scheme (SEIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 50 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.